| Full text | |
| Author(s): Show less - |
Scaramuzzi, Karina
;
Tanaka, Gabriela D.
;
Mariano Neto, Francisco
;
Garcia, Paulo R. A. F.
;
Gabrili, Joel J. M.
;
Oliveira, Denise C. A.
;
Tambourgi, Denise V.
;
Mussalem, Juliana S.
;
Paixao-Cavalcante, Danielle
;
D'Azeredo Orlando, Marcos T.
;
Botosso, Viviane F.
;
Oliveira, Cristiano L. P.
;
Fantini, Marcia C. A.
;
Sant'Anna, Osvaldo A.
Total Authors: 14
|
| Document type: | Journal article |
| Source: | Nanomedicine-Nanotechnology Biology and Medicine; v. 12, n. 8, p. 2241-2250, NOV 2016. |
| Web of Science Citations: | 4 |
| Abstract | |
Due to its physicochemical properties, nanostructured mesoporous SBA-15 silica shows great potential as a vaccine adjuvant. This study evaluated the capacity of SBA-15 to encapsulate/adsorb the recombinant purified HBsAg from the Hepatitis B virus and the immunoresponsiveness of mice orally immunized with HBsAg inside SBA-15. A simulation of small angle X-ray scattering experimental results, together with the nitrogen adsorption isotherms data, allowed to determine the appropriate mass ratio of HBsAg: SBA-15, indicating antigen encapsulation into SBA-15 macroporosity. This was also evaluated by bicinchoninic acid assay and gel electrophoresis. The recruitment of inflammatory cells, an increase in production of specific antibodies, and the non-influence of silica on TH1 or TH2 polarization were observed after oral immunization. Besides, SBA-15 enhanced the phagocytosis of ovalbumin by dendritic cells, an important key to prove how this adjuvant works. Thus, it seems clear that the nanostructured SBA-15 is an effective and safe adjuvant for oral immunizations. (C) 2016 Elsevier Inc. All rights reserved. (AU) | |
| FAPESP's process: | 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling |
| Grantee: | Hugo Aguirre Armelin |
| Support Opportunities: | Research Grants - Research, Innovation and Dissemination Centers - RIDC |